Developing standards for breakthrough therapy designation in oncology

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4297-4304

  Horning, Sandra J ^a   Haber, Daniel A ^b,c   Selig, Wendy K D ^d   Ivy, S Percy ^f   Roberts, Samantha A ^e   Allen, Jeff D ^e   Sigal, Ellen V ^e   Sawyers, Charles L ^c,g  

^a GENENTECH INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Melanoma Research Alliance   (United States)

^e Friends of Cancer Research   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BRENTUXIMAB VEDOTIN; CRIZOTINIB; IBRUTINIB; IVACAFTOR; PALBOCICLIB; VEMURAFENIB; VISMODEGIB;

ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BREAST CANCER; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL DEVELOPMENT PLAN; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HODGKIN DISEASE; HUMAN; INTERNATIONAL COOPERATION; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; THERAPEUTICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84882953749     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0523     Document Type: Article

References (9)

1. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011;364:1087-9.
2. Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 2012;9:208-14.
3. FDA. Driving Biomedical Innovation: Initiatives to Improve Products for Patients2011:[19-20 pp.]. [Cited: Apr. 15, 2013]. Available from: www.fda.gov/innovation.
4. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Health Aff 2011;30:1375-81.
5. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
6. Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS Regulatory review of novel therapeutics-comparison of three regulatory agencies. N Engl J Med 2012;366:2284-93.
7. Fleming T, Sekeres M, Lieberman G, Korn E, Wilson W, Woodcock J, et al. Development Paths for New Drugs with Large Treatment Effects Seen Early. Conference on Clinical Cancer Research [Internet]; 2011. [Cited: Apr. 15, 2013]. Available from: http://www.focr.org/sites/default/files/Panel4FINAL11411.pdf.
8. FDA. Draft Guidance for Industry and Food and Drug Administration Staff-In vitro Companion Diagnostic Devices. [Internet]; 2011. [Cited: Apr. 15, 2013]. Available from: http://www.fda.gov/medicaldevices/ deviceregulationandguidance/guidancedocuments/ucm262292.htm.
9. FDA. General Principles: EMEA-FDA Parallel Scientific Advice 2009. [Cited: Apr. 15, 2013]. Available from: http://www.fda. gov/ InternationalPrograms/FDABeyondOurBordersForeignOffices/EuropeanUnion/ EuropeanUnion/EuropeanCommission/ucm114345. htm.